Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - OtherRevenue (Gross)Shares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Design Therapeutics (DSGN) Preferred Shares Issued (2020 - 2021)

Design Therapeutics' Preferred Shares Issued history spans 2 years, with the latest figure at $124.7 million for Q1 2021.

  • On a quarterly basis, Preferred Shares Issued rose 179.0% to $124.7 million in Q1 2021 year-over-year; TTM through Dec 2021 was $124.7 million, a 178.8% increase, with the full-year FY2021 number at $124.7 million, up 178.8% from a year prior.
  • Preferred Shares Issued hit $124.7 million in Q1 2021 for Design Therapeutics, up from $31000.0 in the prior quarter.
  • Over the last five years, Preferred Shares Issued for DSGN hit a ceiling of $124.7 million in Q1 2021 and a floor of $31000.0 in Q2 2020.